113 related articles for article (PubMed ID: 34855660)
1. Temporal Trends in Glioblastoma Survival: Progress then Plateau.
Neth BJ; Carabenciov ID; Ruff MW; Johnson DR
Neurologist; 2022 May; 27(3):119-124. PubMed ID: 34855660
[TBL] [Abstract][Full Text] [Related]
2. Survival benefit of glioblastoma patients after FDA approval of temozolomide concomitant with radiation and bevacizumab: A population-based study.
Zhu P; Du XL; Lu G; Zhu JJ
Oncotarget; 2017 Jul; 8(27):44015-44031. PubMed ID: 28467795
[TBL] [Abstract][Full Text] [Related]
3. Glioblastoma survival in the United States before and during the temozolomide era.
Johnson DR; O'Neill BP
J Neurooncol; 2012 Apr; 107(2):359-64. PubMed ID: 22045118
[TBL] [Abstract][Full Text] [Related]
4. Glioblastoma in the elderly: the effect of aggressive and modern therapies on survival.
Babu R; Komisarow JM; Agarwal VJ; Rahimpour S; Iyer A; Britt D; Karikari IO; Grossi PM; Thomas S; Friedman AH; Adamson C
J Neurosurg; 2016 Apr; 124(4):998-1007. PubMed ID: 26452121
[TBL] [Abstract][Full Text] [Related]
5. Improved survival time trends for glioblastoma using the SEER 17 population-based registries.
Koshy M; Villano JL; Dolecek TA; Howard A; Mahmood U; Chmura SJ; Weichselbaum RR; McCarthy BJ
J Neurooncol; 2012 Mar; 107(1):207-12. PubMed ID: 21984115
[TBL] [Abstract][Full Text] [Related]
6. Clinical features associated with the efficacy of chemotherapy in patients with glioblastoma (GBM): a surveillance, epidemiology, and end results (SEER) analysis.
Wen J; Chen W; Zhu Y; Zhang P
BMC Cancer; 2021 Jan; 21(1):81. PubMed ID: 33468109
[TBL] [Abstract][Full Text] [Related]
7. Adult glioblastoma multiforme survival in the temozolomide era: a population-based analysis of Surveillance, Epidemiology, and End Results registries.
Darefsky AS; King JT; Dubrow R
Cancer; 2012 Apr; 118(8):2163-72. PubMed ID: 21882183
[TBL] [Abstract][Full Text] [Related]
8. Patterns of glioblastoma treatment and survival over a 16-years period: pooled data from the German Cancer Registries.
Efremov L; Abera SF; Bedir A; Vordermark D; Medenwald D
J Cancer Res Clin Oncol; 2021 Nov; 147(11):3381-3390. PubMed ID: 33743072
[TBL] [Abstract][Full Text] [Related]
9. Giant cell glioblastoma: a glioblastoma subtype with distinct epidemiology and superior prognosis.
Kozak KR; Moody JS
Neuro Oncol; 2009 Dec; 11(6):833-41. PubMed ID: 19332771
[TBL] [Abstract][Full Text] [Related]
10. Time trends in glioblastoma multiforme survival: the role of temozolomide.
Dubrow R; Darefsky AS; Jacobs DI; Park LS; Rose MG; Laurans MS; King JT
Neuro Oncol; 2013 Dec; 15(12):1750-61. PubMed ID: 24046259
[TBL] [Abstract][Full Text] [Related]
11. Overall survival in patients with glioblastoma before and after bevacizumab approval.
Johnson DR; Omuro AMP; Ravelo A; Sommer N; Guerin A; Ionescu-Ittu R; Shi S; Macalalad A; Uhm JH
Curr Med Res Opin; 2018 May; 34(5):813-820. PubMed ID: 29025274
[TBL] [Abstract][Full Text] [Related]
12. A Real-World Claims Analysis of Costs and Patterns of Care in Treated Patients with Glioblastoma Multiforme in the United States.
Norden AD; Korytowsky B; You M; Kim Le T; Dastani H; Bobiak S; Singh P
J Manag Care Spec Pharm; 2019 Apr; 25(4):428-436. PubMed ID: 30917077
[TBL] [Abstract][Full Text] [Related]
13. First-line bevacizumab contributes to survival improvement in glioblastoma patients complementary to temozolomide.
Hata N; Mizoguchi M; Kuga D; Hatae R; Akagi Y; Sangatsuda Y; Amemiya T; Michiwaki Y; Fujioka Y; Takigawa K; Suzuki SO; Yoshitake T; Togao O; Hiwatashi A; Yoshimoto K; Iihara K
J Neurooncol; 2020 Feb; 146(3):451-458. PubMed ID: 32020475
[TBL] [Abstract][Full Text] [Related]
14. Glioblastoma Treatment with Temozolomide and Bevacizumab and Overall Survival in a Rural Tertiary Healthcare Practice.
Carter TC; Medina-Flores R; Lawler BE
Biomed Res Int; 2018; 2018():6204676. PubMed ID: 30687753
[TBL] [Abstract][Full Text] [Related]
15. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
Chinot OL; Wick W; Mason W; Henriksson R; Saran F; Nishikawa R; Carpentier AF; Hoang-Xuan K; Kavan P; Cernea D; Brandes AA; Hilton M; Abrey L; Cloughesy T
N Engl J Med; 2014 Feb; 370(8):709-22. PubMed ID: 24552318
[TBL] [Abstract][Full Text] [Related]
16. A clinical trial of bevacizumab, temozolomide, and radiation for newly diagnosed glioblastoma.
Narayana A; Gruber D; Kunnakkat S; Golfinos JG; Parker E; Raza S; Zagzag D; Eagan P; Gruber ML
J Neurosurg; 2012 Feb; 116(2):341-5. PubMed ID: 22035272
[TBL] [Abstract][Full Text] [Related]
17. Gamma Knife Stereotactic Radiosurgery in Combination with Bevacizumab for Recurrent Glioblastoma.
Morris SL; Zhu P; Rao M; Martir M; Zhu JJ; Hsu S; Ballester LY; Day AL; Tandon N; Kim DH; Shepard S; Blanco A; Esquenazi Y
World Neurosurg; 2019 Jul; 127():e523-e533. PubMed ID: 30954746
[TBL] [Abstract][Full Text] [Related]
18. Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years.
Ohno M; Miyakita Y; Takahashi M; Igaki H; Matsushita Y; Ichimura K; Narita Y
Radiat Oncol; 2019 Nov; 14(1):200. PubMed ID: 31718669
[TBL] [Abstract][Full Text] [Related]
19. Glioblastoma management in the temozolomide era: have we improved outcome?
Lwin Z; MacFadden D; Al-Zahrani A; Atenafu E; Miller BA; Sahgal A; Menard C; Laperriere N; Mason WP
J Neurooncol; 2013 Nov; 115(2):303-10. PubMed ID: 23979682
[TBL] [Abstract][Full Text] [Related]
20. National Trends for Reoperation in Older Patients with Glioblastoma.
Chen YR; Sole J; Ugiliweneza B; Johnson E; Burton E; Woo SY; Koutourousiou M; Williams B; Boakye M; Skirboll S
World Neurosurg; 2018 May; 113():e179-e189. PubMed ID: 29427817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
